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Molecular genetics of ion channel diseases. Many physiological pro-
cesses depend upon the proper functioning of plasma membrane ion
channels. This is most apparent in absorptive and secretory epithelia, and
in electrically excitable tissues such as nerve and muscle. Disturbances in
the operation of ion channels in these settings can alter normal physiology
and cause disease. This review illustrates the use of molecular genetics in
identifying hereditaty diseases caused by mutations in genes which encode
various skeletal muscle ion channels. Recent advances in the discovery of
genetic mutations in the skeletal muscle voltage-gated sodium channel in
certain forms of periodic paralysis, mutations in the skeletal muscle
chloride channel gene in myotonia congenita, and defects in two distinct
calcium channels that underlie disorders of excitation-contraction cou-
pling (murine muscular dysgenesis, malignant hyperthermia susceptibility)
will be presented. In each case, prior knowledge of abnormal ion channel
function prompted the search for mutations in candidate genes. This work
is beginning to shed new light on the relationship between ion channel
structure and function by studies of naturally occurring channel mutations.
The characterization of the structure and function of ion
channels is an area under intense investigation. In the past few
years, work with recombinant complementary DNAs (cDNAs)
encoding various ion transport proteins has greatly accelerated
the rate of new discoveries in the field. By engineering site-specific
mutations in a recombinant molecule and assaying function of the
expressed mutant protein, many investigators have begun to
discern important relationships between primary structure and
function. In most cases, selection of amino acid residues as targets
for mutagenesis has been guided by hypotheses derived from
relevant experimental data. Recently, new insights into the struc-
ture and function of certain ion channels have emerged unexpect-
edly from work in human genetics. In the past few years a small
number of hereditary syndromes have been identified that are
caused by genetic mutations in an ion channel gene. These "ion
channelopathies" provide models for ion channel dysfunction and
new opportunities to define functionally important structures in
the channel proteins. In most cases, ion channel mutations were
sought because of prior information implicating a disturbance in
channel function as the pathophysiological basis for a particular
disease phenotype.
Candidate gene approach to ion channel diseases
Defining a genetic abnormality at the level of nucleotide
sequence is a formidable task. In the past decade, advances in the
use of genetic linkage analysis have greatly facilitated the identi-
fication of many disease producing loci. Using an approach called
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positional cloning, the location of a genetic locus responsible for
a given hereditary syndrome can be identified without prior
knowledge of the biochemical or physiological abnormalities
underlying the disease process. This is accomplished by examining
affected pedigrees for genetic linkage to anonymous polymorphic
markers distributed at intervals throughout the genome. Using a
systematic approach, a region may eventually be found that is
"linked" to the syndrome as defined by a low rate of recombina-
tion between the marker locus and the disease locus.
An alternative approach for defining genetic defects takes
advantage of known physiological or biochemical abnormalities
ascertained in a particular hereditary disease. In this strategy,
known as the candidate gene approach, genes encoding proteins
that are logical candidates for maintaining the normal phenotype
of the process altered in the disease condition are first identified.
Candidate genes are then examined for genetic linkage to the
hereditary disease of interest, and then if appropriate, a gene is
screened for mutations. With the development of rapid molecular
cloning techniques, the pool of identified genes with defined
functions has increased allowing the candidate gene approach to
be more feasible.
This review illustrates the use of molecular genetics to define
and characterize ion channel gene defects responsible for certain
hereditary diseases affecting skeletal muscle. This discussion is
organized around recent work done to identify genetic mutations
in channels that participate in two of the principle physiologic
events leading to muscle contraction: excitation, and excitation-
contraction coupling (Table 1).
Disorders of skeletal muscle membrane excitation
The intrinsic property of the skeletal muscle membrane to
initiate and conduct action potentials in response to synaptic input
at the neuromuscular junction is termed excitation [1]. Action
potentials are regenerative, propagated electrical waves resulting
from rapid transitions of ion fluxes across the sarcolemma that
depend upon the normal functioning of a specialized group of ion
channels that "gate" in response to changes in membrane poten-
tial.
Voltage-gated ion channels have unique biophysical properties
that underlie their behavior. According to the model developed by
Hodgkin and Huxley from their pioneering work with the squid
giant axon [2], changes in the ionic permeability of excitable
membranes are controlled by two kinetic processes: activation and
inactivation. In muscle and nerve, a sudden membrane depolar-
ization causes a rapid rise in local Na permeability due to the
opening (activation) of voltage-gated Na channels. This rise in
Na permeability is transient owing to the second process of
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Table 1. Hereditary diseases of skeletal muscle ion channels
Sodium channel (SCN4Aa, 17q')
Hyperkalemic periodic paralysis (HYPP)
Paramyotonia congenita (PC)
Chloride channel (CLCNI, 7q)
Myotonia congenita (Thomsen's disease)
Recessive generalized myotonia (RGM)
Calcium-release channel/iyanodine receptor (RYRI, 19q)
Malignant hyperthermia susceptibility (MHS)
Central core disease (CCD)
Dihydropyridine-sensitive calcium (CACNL1A3, lq)
Muscular dysgenesis (mouse)
Hypokalemic periodic paralysis
a Locus name or gene symbol
h Human chromosomal assignment
inactivation. The Hodgkin-Huxley model predicts that Na chan-
nels can exist in at least three kinetic states: a closed (non-
conducting) but activatable state, open or activated (conducting),
and inactivated (non-conducting). Repolarization of the mem-
brane potential is required for Na channels to re-enter the
closed state and be available again to initiate the next action
potential. This is accomplished by the opening of voltage-gated
potassium channels that allow potassium ions to flow out of the
cell and drive the membrane potential toward more hyperpolar-
ized voltages. In addition, voltage-sensitive chloride channels
confer a relatively fixed high degree of membrane C1 permeabil-
ity that contributes to repolarization and serves to stabilize the
membrane potential [3].
Clinical manifestations
Disturbances in the function of any of the components required
for action potential generation or repolarization can affect the
ability of skeletal muscle to contract or to autoregulate its
contractile activity. Two principle symptoms may arise from
abnormal sarcolemmal excitability: myotonia and periodic paral-
ysis.
Myotonia is a symptom experienced by patients affected with a
variety of acquired and hereditary neuromuscular diseases and
has multiple pathophysiological mechanisms [4, 5]. It is charac-
terized by delayed relaxation of muscle following a sudden
forceful voluntary contraction and is associated with repetitive
generation of muscle action potentials. The presence of myotonia
is most often described by the patient as painless muscle stiffness.
Other specific qualities of myotonia may help to differentiate
certain clinical syndromes from one another [6]. In myotonia
congenita, muscle stiffness is typically most severe after a period
of inactivity, but remits gradually with continued movement
("warm-up" phenomenon) [7]. The syndrome may be genetically
transmitted as either an autosomal dominant (Thomsen's disease)
or recessive (recessive generalized myotonia, RGM) allele. Pa-
tients with myotonia congenita often exhibit hypertrophy of limb
muscles and generally do not experience attacks of weakness. In
contrast, myotonia in some patients develops upon exposure to
cold, or ingestion of potassium salts and is aggravated by exercise
(paradoxical myotonia). The latter is characteristic of the autoso-
mal dominant disease, paramyotonia congenita (PC).
The other principle symptom in disorders of muscle membrane
excitability is periodic paralysis. Periodic paralysis is characterized
by episodic weakness or paralysis of voluntary muscles occurring
in the absence of neuromuscular junction or motor neuron disease
[71. Attacks of weakness are often associated with changes in the
serum K concentration as a result of abrupt redistribution of
intracellular and extracellular Kt Periodic paralysis most often
occurs as a familial condition segregating as an autosomal domi-
nant trait, and is typically classified as either hypokalemic, hy-
perkalemic, or normokalemic. Curiously, some individuals with
hyperkalemic periodic paralysis (HYPP) exhibit myotonia
whereas some PC patients have attacks of hyperkalemic weakness.
This has suggested to some that the two disorders are extreme
presentations of a single disease [8].
Pathophysiology of myotonia and periodic paralysis
Electrophysiological studies have determined that both myoto-
nia and periodic paralysis are associated with abnormal muscle
cell membrane ionic conductances [9]. In 1962, Bryant first noted
the striking similarities between muscle from the congenitally
myotonic goat and normal goat muscle bathed in chloride-free
solution [10]. These observations led to the proposal that myoto-
nia is caused by reduced sarcolemmal chloride conductance (g1)
and that congenital myotonia may be a disorder in which an
intrinsic defect in membrane chloride permeability exists. This
hypothesis was subsequently confirmed by the direct measure-
ment of reduced sarcolemmal g1 in myotonic goat muscle [11], in
excised intercostal muscle fibers from human myotonia congenita
[12], and in the myotonic ADR mouse [13]. The pathophysiology
of myotonia due to depressed g1 stems from electrical instability
of the muscle membrane potential and a tendency to exhibit
hyperexcitability. Normally, muscle g1 accounts for approxi-
mately 70% of total resting membrane ionic conductance and
helps stabilize the membrane potential action potentials [3].
Without this stabilizing gcj, the rise in K concentration that
occurs within the transverse tubule (t-tubule) during action po-
tential propagation can produce a depolarizing after-potential
capable of inducing repetitive, self-triggering electrical activity
[14].
Subsequent work by Lehmann-Horn, Rudel and Ricker pro-
vided evidence for a different mechanism of myotonia [15]. Using
excised intercostal muscle fibers from PC patients for in vitro
voltage-clamp recording, these investigators observed spontane-
ous depolarization of the membrane potential when the fibers
were cooled to 27°C. The cooled, depolarized fibers initially
exhibited a high level of spontaneous electrical and mechanical
activity and then became electrically inexcitable. The spontaneous
depolarization could be prevented by tetrodotoxin (TIX), which
blocks voltage-gated Na channels.
Similarly, muscle fibers excised from patients with hypokalemic
and hyperkalemic periodic paralysis exhibit spontaneous depolar-
izations and concomitant inexcitability upon exposure to either
reduced (hypokalemic periodic paralysis) or elevated (HYPP)
extracellular K concentrations [16, 17]. However, there were
important differences observed that suggested pathophysiologic
heterogeneity between the two syndromes. In hypokalemic peri-
odic paralysis, the resting membrane potential is 10 to 15 mV less
negative than control fibers even in normal extracellular K, and
TTX has no effect on the spontaneous depolarization in the low
K environment [17]. In contrast, membrane depolarization in
HYPP fibers can be blocked by 1TFX and the resting membrane
potential in normal K is similar to control fibers. Further proof
that the spontaneous depolarization seen in these experiments is
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caused by abnormal voltage-gated Na1 channels was obtained by
Cannon, Brown and Corey [181. Using the patch clamp technique,
these investigators identified a subpopulation of Na channels in
cultured HYPP myotubes that exhibited non-inactivating behav-
ior in elevated extracellular Kt
Based on the collective work of many investigators in the past
three decades, it became clear that some forms of congenital
myotonia and hereditary periodic paralysis were due to defects in
the control of either sarcolemmal chloride or sodium permeabil-
ity. The next step in defining these physiologic abnormalities at a
molecular level awaited the identification and structural charac-
terization of skeletal muscle voltage-gated Na and chloride
channels and examination of each as a candidate gene for these
various disorders.
Muscle Na channel diseases
Sodium channel proteins from mammalian brain, muscle, and
myocardium have been well characterized and are known to
consist of a large (Mr — 260 kD) a-subunit and one or two smaller
/3 subunits [191. In 1989, Trimmer et al reported the cDNA
cloning and functional expression of a distinct rat Na channel
a-subunit isoform, designated gI, that is expressed exclusively in
skeletal muscle [20]. The deduced 1840 amino acid sequence
exhibits —80% similarity with isoforms cloned from rat brain.
Heterologous expression of j.rI in Xenopus oocytes resulted in
voltage-dependent Na currents that were highly sensitive to both
TFX and js-conotoxin, similar to the native channel. The cloning
of jil set the stage for subsequent work that led to identification
of the gene responsible for certain types of periodic paralysis and
myotonia.
Molecular genetics
To examine j.tI as a candidate gene for hereditary muscle
diseases, homologous human cDNAs were isolated [21, 22] and
used to determine the location of the gene, designated SCN4A
(17q23.1 to 25.2) [22, 23], and to define restriction fragment
length polymorphisms [22, 24]. Several multigeneration families
affected with various forms of periodic paralysis were next exam-
ined for linkage to SCN4A or the neighboring growth hormone
(OH) locus. These studies demonstrated tight linkage of the
SC'N4A/GH complex to the phenotypes I-IYPP [22, 25] and PC
[26, 27], but not to hypokalemic periodic paralysis [28]. This data
provided further support for the hypothesis that the skeletal
muscle Na1 channel gene was involved in the pathogenesis of
some forms of periodic paralysis and myotonia, that HYPP and
PC were likely to be allelic disorders of the same gene, and that
non-allelie genetic heterogeneity exists among the periodic paral-
yses. Linkage to SCN4A has also been demonstrated to an atypical
form of myotonia congenita which exhibits responsiveness to
acetazolamide treatment [29], but typical autosomal dominant
myotonia congenita (Thomsen's disease) is not linked to SCN4A
[30].
After establishment of genetic linkage between the SCN4AIGH
complex on 17q and the HYPP/PC phenotypes, a direct search for
specific disease-associated mutations in the Na channel coding
sequence was undertaken. Two strategies were devised to accom-
plish this task using available eDNA sequence [31]. Ptdèek and
co-workers analyzed single-strand conformation polymorphisms
(SSCP) in a set of overlapping reverse-transcriptase polymerase
chain reaction (RT-PCR) products obtained from HYPP muscle
RNA [32]. An SSCP abnormality corresponding to the SS segment
of domain 2 was observed co-segregating with the disease pheno-
type in three HYPP families and was absent in normal chromo-
somes. Sequencing of the abnormal band revealed a C to T
transition resulting in a missense mutation in codon 704. This
mutation occurs in a highly conserved region of the channel and
causes the substitution of a threonine residue with methionine.
Similarly, Rojas et al used cross-species eDNA cloning of the
HYPP Na channel by the RT-PCR method [33]. Using this
approach which required the sequencing of multiple independent
recombinant RT-PCR recombinants (—150,000 base pairs), a
single nucleotide change (A to 0) was discovered. This mutation
causes the replacement of valine for methionine at codon 1592 in
the S6 segment of domain 4. These two studies firmly established
that SGN4A was the gene responsible for HYPP.
SCN4A mutations have also been discovered in PC patients. To
facilitate the search for mutations without requiring muscle tissue,
the complete genomic organization of SCN4A was defined [34,
35]. The gene consists of 24 exons and spans 32 to 35 kb of
genomic DNA. To screen patient DNA for mutations, several
pairs of oligonucleotide primers were designed from flanking
intron sequence that allowed PCR amplification of individual
exons. Mutations were then identified by either direct sequencing
of amplified exons, or by SSCP analysis. McClatchey et al reported
two distinct mutations in families with PC that involved residues
in the highly conserved cytoplasmic loop between domains 3 and
4 that is known to have an important role in channel inactivation
[36]. Subsequently, Ptáëek et al identified mutations affecting a
highly conserved arginine residue at codon 1448 in PC patients
[37]. The 1448 codon encodes the most extracellular arginine
residue in the S4 helix of domain 4, a structure implicated in
channel activation [38]. To date, there have been 15 reported
SCN4A mutations [32, 33, 36, 37, 39—41] (Fig. 1). One of these
has been found in hyperkalemic periodic paralysis affecting quar-
ter horses [42]. All mutations so far identified are missense-amino
acid substitutions in highly conserved regions of the Na channel
protein sequence. It is clear from this work that considerable
molecular heterogeneity exists in HYPP and PC.
Functional characterization of mutant Na + channels
The final proof that a given mutation in the Na channel gene
is functionally significant can be provided by in vitro expression of
recombinant channels modified by site-directed mutagenesis. Sev-
eral SCN4A mutations have so far been functionally characterized
and the corresponding biophysical abnormalities correlated with
the respective phenotype. SCN4A mutations found in both HYPP
and PC affect channel gating in distinct ways.
Two groups have reported data characterizing the functional
abnormalities associated with HYPP mutations expressed in the
rat pJ channel. The mutant channels exhibit persistent late
current in whole-cell patch-clamp recordings without any change
in permeation properties of the channel [43, 44]. This finding
agreed well with in vitro recordings made from cultured HYPP
myotubes [18] and was felt to be consistent with the underlying
defect in the disease. The two reports differ in their explanation of
this phenomenon. Work by Cannon and Strittmater described a
defect in Na channel inactivation that produced an increase
frequency of channel re-openings during depolarizations and an
increase in open times [43]. In contrast, Cummins et al demon-
strated a 10 to 15 mV shift in the voltage-dependence of activation
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of the mutant channel as compared to the wild-type (WT). The
latter finding was felt to result in a persistent Na current that is
activated at —70 mV [4I. These data suggest that mutant Na
channels can maintain the membrane in a depolarized state after
an action potential, cause inactivation of normal channels and
result in electrical inexcitability of the muscle.
Two PC mutations that replace a highly conserved arginine
residue in the S4 segment of domain 4 (R1448) were studied by
Chahine et al using the recombinant human skeletal muscle Na *
channel [5I. Despite expectations that S4 mutations would
disrupt Na channel activation, both mutations have profound
effects on the rate and voltage-dependence of inactivation with
little effect on activation (Fig. 2A). In addition, PC mutants
exhibit an enhanced rate of recovery from inactivation, a finding
that suggested the inactivated state of the channel is destabilized.
Analysis of single channel recordings for both mutants revealed
evidence for an uncoupling of activation and inactivation (Fig.
2B), and these authors suggested a critical role for the domain 4
S4 helix in this coupling. Additional studies performed on other
PC mutants demonstrate a similar in vitro biophysical phenotype
consisting of slow inactivation, accelerated recovery from inacti-
vation, and a shift in the voltage-dependence of steady-state
inactivation [46]. This constellation of functional abnormalities is
believed to induce a state of sarcolemmal hyperexcitability and
predispose to the development of myotonia.
Muscle CF channel diseases
The role of reduced sarcolemmal g1 in the pathophysiology of
certain forms of myotonia implicated skeletal muscle chloride
channels as candidate genes for myotonia congenita in man and
experimental animals. However, little progress was made in
exploring this hypothesis until a breakthrough in our understand-
ing of muscle chloride channel structure occurred.
Using a novel expression cloning technique, Jentsch, Stein-
meyer and Schwarz [47] successfully isolated cDNAs encoding a
voltage-gated chloride channel (CIC-0) from the electric organ of
the ray Torpedo martnorata. The deduced primary sequence (805
amino acids) is unique and bears no similarity to any previously
cloned gene including various ligand-gated chloride conducting
neurotransmitter receptors (GABA, glycine), the cystic fibrosis
transmembrane conductance regulator (CFTR), and the erythro-
cyte anion exchanger. The predicted secondary structure of the
C1C-0 protein was compatible with an ion channel having 12
hydrophobic putative membrane spanning segments. Functional
expression of full-length C1C-0 in Xenopus oocytes revealed
chloride selective currents exhibiting complex gating and perme-
ation properties similar to reconstituted T californica chloride
channels. These findings support the conclusion that a single
polypeptide is sufficient for activity of the Torpedo chloride
channel [48].
Since electric organ and skeletal muscle have similar embryo-
logical origins, it was hypothesized that a chloride channel homol-
ogous to CIC-0 might be expressed in mammalian skeletal muscle.
Using the C1C-0 cDNA as a probe, Steinmeyer, Ortland and
Jentsch [49] succeeded in cloning cDNAs encoding a chloride
channel isoform from adult rat skeletal muscle (C1C-1) that
exhibits 54% overall amino acid sequence homology with the
Torpedo channel, and has developmentally regulated expression in
skeletal muscle. Heterologously expressed CIC-1 channels in
Xenopus oocytes exhibit properties resembling the predominant
chloride currents in native skeletal muscle [3]. Furthermore,
expressed CIC-1 currents can be blocked by 9-anthracene-carbox-
ylic acid, a compound capable of inducing myotonia in normal rats
[50]. Based on these findings, dC-i was postulated to be the
predominant skeletal muscle chloride channel and an excellent
candidate for the myotonia congenita gene.
Molecular genetics
The first studies to examine the role of did-i in myotonia
utilized the ADR (for "arrested development of righting") myo-
tonic mouse. This strain of mice exhibits a severe congenital
myotonia transmitted as an autosomal recessive allele. Investiga-
tions demonstrated abnormal skeletal muscle dC-i mRNA tran-
scripts and an altered restriction pattern of genomic DNA from
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Fig. 2. Functional expression of paramyotonia congenita Na channel mutations. A. Whole-cell current recordings from cells expressing recombinant
wild-type (WT), or mutant (R1448H, R1448C) human skeletal muscle Na channels. B. Typical single channel recordings from the same three expressed
channel alleles. (From Chahine et al [45]; used with permission).
homozygous adr/adr mice [511. Cloning of dC-i eDNA from
adrladr revealed the insertion of a transposon element into the
coding region of the gene interrupting the transcription of chlo-
ride channel sequences. Using interspecies backcrosses, the mu-
rine C1C-1 gene was mapped to chromosome 6 close to the Tcrb
locus [51]. These studies provided the first direct proof that a
chloride channel defect was responsible for myotonia. Additional
missense and nonsense point mutations have also been identified
as the probable cause for myotonia in other allelic variants of
ADR [52].
Two groups have now reported linkage studies of human
myotonia congenita that provide evidence for an association of
the muscle chloride channel gene with this disease as well. Koch
et al [531 described partial eDNA cloning of human C1C-1
(hClC-1), identification of an NsiI restriction fragment length
polymorphism (RFLP) within the coding region of the gene, and
demonstrated linkage to both recessive and dominant myotonia
congenita. Similarly, Abdalla et al [54] took advantage of the
known synteny between mouse chromosome 6 in the region of
dC-i and human 7q, and demonstrated linkage of the TCRI3
locus to expression of Thomsen's disease in four families.
Mutations in the hClC-1 gene (designated CLCN1) have now
been identified in patients with either recessive or dominant
myotonia congenita. Koch et al described a T —G transversion
affecting nt. 1238 of the hClC-1 coding sequence in RGM patients
identified by analysis of the NsiI RFLP [53]. This single nucleotide
change accounts for the appearance of a new NsiI cleavage site
and encodes for cysteine at codon 413 instead of the normal
phenylalanine. This residue is located in the eighth transmem-
brane segment and is completely conserved in all members of this
chloride channel family. Many RGM patients are heterozygous
for this mutation suggesting the existence of an unidentified
second mutation (compound heterozygosity) [55].
George et al screened DNA from four Thomsen's disease
families in which strong linkage had been demonstrated to the
TCRJ3 locus [56]. Using oligonucleotide primers designed from
partially characterized CLCN1 genomic sequence, SSCP analysis
was used to search for potential mutations. In three of the four
families, an aberrant SSCP pattern was observed in exon 5 of all
affected but none of the unaffected individuals. Direct sequencing
of the abnormal conformer revealed a G —' A transition at
nucleotide 689 in the coding sequence. This single base change
causes the substitution of a highly conserved glycine residue at
position 230 with glutamic acid (G230E). This probable mutant
allele was not found in > 100 normal control DNA samples and
is believed to be a disease producing mutation.
Functional characterization of mutant Cl channels
Functional studies demonstrating the significance of Thomsen's
disease mutations are indirectly helping to determine the subunit
stoichiometry of the dC-i channel complex. In the heterozygous
state of RGM carriers and Thomsen's disease patients, it is
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Fig. 3. Structures involved in skeletal muscle excitation-contraction coupling. A. Electron micrograph of rabbit skeletal muscle in longitudinal thin section
showing locations of two triad junctions. B. Higher magnification of a single triad junction showing transverse tubule (TI), terminal cisternae of
sarcoplasmic reticulum (TC), and electron dense foot structures (FS) interposed between the two membranes (From Fleischer and Inui [97]; used with
permission).
expected that 50% of the expressed channels are from a normal
allele and yet reduction of g1 to levels far lower than 50% is
required for myotonia to occur [57]. It is speculated that certain
CLCN1 mutations exert a dominant-negative effect on the func-
tion of the normal chloride channel allele. This issue was elegantly
examined by Steinmeyer et al by co-expression studies of wild-type
(WT) and mutant human C1C-1 channels inXenopus oocytes [58].
These investigators constructed mutant hCIC-1 channels corre-
sponding to two mutations including an allele identified in de-
scendants of Dr. Julius Thomsen for whom the disease is named.
When expressed alone, mutant alleles G230E and P480L exhibit
no chloride current in the physiological voltage range, suggesting
that the channels are rendered non-functional by the mutations.
In co-expression experiments, G230E and P480L progressively
inhibited expression of the WT chloride channel allele to a greater
extent than a non-specific co-expressed cRNA. Thus these results
suggest that co-expression of mutants has a greater effect on WT
expression than would be expected from simple competition for
translation, and this was interpreted as evidence that the func-
tional form of the C1C-1 channel is a multimer [58]. Additional
work will be required to define the precise role of these mutant
residues in normal channel function.
Disorders of excitation-contraction coupling
Abnormal skeletal muscle membrane properties leading to
either paralysis or excessive contraction may occur also in certain
hereditary conditions affecting events that follow excitation. Prop-
agated skeletal muscle action potentials eventually reach the
t-tubules, a network of narrow plasma membrane invaginations
that penetrate deeply into the muscle fiber core. Here an electrical
signal triggers the release of stored Ca2 from the sarcoplasmic
reticulum (SR) and a contraction occurs. The transduction of
membrane depolarization into Ca2 release is called excitation-
contraction (E-C) coupling. This process depends upon the
functioning of two vital ion channels, the dihydropyridine-sensi-
tive Ca2 channel and the SR Ca2-release channel. Molecular
genetics has not only served to identify disease producing muta-
tions in these channels, but has also helped demonstrate their role
in normal E-C coupling.
Histologically, E-C coupling takes place at the convergence of
t-tubular membranes with the terminal cisternae of the SR in
structures known as triad junctions. Ultrastructural studies have
identified large, electron-dense structures known as foot processes
interposed between the t-tubule and SR membranes [59] (Fig. 3).
These structures were thought to form a physical link between the
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Fig. 4. Schematic illustration of the spatial relationship between the dihydropyridine receptor located in the t-tubular membrane (TI') and the yanodine
receptor in the sarcoplasmic reticulum membrane (SR) (after Takeshima et al [83]).
two membranes and thus were likely to be involved in E-C
coupling. Biochemical evidence subsequently identified these
structures as the receptor for ryanodine, a plant alkaloid that
binds to and modulates the SR Ca2-release channel [60]. Later,
reconstitution of the purified ryanodine-receptor (RyR) in planar
lipid bilayers demonstrated its function also as a Ca2-release
channel [61].
Separate from the SR Ca2 release mechanism, voltage-sensors
were postulated to exist in the t-tubule that sense changes in
membrane potential and trigger SR Ca2 release. The triggering
of SR Ca2 release by this voltage-sensor was thought to occur
concomitant with the detectable movement of ionic charges
through the t-tubule membrane [62]. Receptors for the Ca2
channel blocking dihydropyridines are abundantly present in
t-tubular membranes and were therefore considered likely candi-
dates for this proposed voltage-sensor. Indirect evidence for the
involvement of the dihydropyridine receptor (DHPR) in E-C
coupling was provided by Rios and Brum [63] in experiments
demonstrating parallel inhibition of t-tubular intramembranous
charge movement and SR Ca2 release by dihydropyridines.
Later, cloning of the rabbit skeletal muscle DHPR cDNA re-
vealed a structural motif similar to the voltage-gated Na '-channel
(Fig. 4) [64], suggesting that it may also function as an ion
channel, most likely accounting for the prominent slow inward
Ca2 current observed in skeletal muscle [65]. However, skeletal
muscle E-C coupling does not require extracellular Ca2 move-
ment into the myoplasm [66] and the identity of the skeletal
muscle DHPR as a voltage-gated Ca2 channel was confounded
by the observation that less than 5% of dihydropyridine binding
sites in t-tubular membranes represent functional Ca2 channels
[67]. These matters were greatly clarified by studies of the
muscular dysgenesis mouse [681.
Murine muscular dysgenesis
Muscular dysgenesis (mdg) is a lethal, autosomal recessive
murine disease characterized by congenital paralysis of skeletal
muscle [69]. Studies of dysgenic muscle demonstrated absence of
the slow inward Ca2 current, selective reduction in skeletal
muscle dihydropyridine binding, substantial reduction in in-
tramembranous charge movement, and failure of E-C coupling
[70—72]. In 1988, Tanabe et al reported differences between
normal and homozygous mdg!mdg mice in the pattern of genomic
DNA restriction fragments hybridizing to probes derived from the
rabbit DHPR cDNA [73]. In addition, Northern blot analysis
demonstrated greatly reduced levels of the DHPR transcript in
dysgenic muscle. Evidence supporting an hypothesis that absence
of functional DHPR caused the mdg phenotype was provided by
experiments in which an expression plasmid encoding the rabbit
muscle DHPR was microinjected into nuclei of cultured dysgenic
myotubes. Expression of DHPR simultaneously repaired the
defect in E-C coupling, as evidenced by the emergence of
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spontaneous and electrically stimulated contractions in the cul-
tured cells, and conferred the cells with slow inward Ca2 currents
[73]. Injected myotubes also exhibit restoration of intramembra-
nous charge movement [72]. These landmark studies not only
elucidated the cause of muscular dysgenesis, but also revealed the
function of the DHPR as a voltage-gated Ca2 channel and an
essential component of E-C coupling. Later studies by Chaudhari
identified a single nucleotide deletion and resulting frame shift
mutation in the mdg allele that would prevent translation of a
functional Ca2 channel protein and presumably destabilizes the
corresponding mRNA [74].
Although there is no known human disease correlate of murine
muscular dysgenesis, there has recently been genetic linkage
demonstrated between familial hypokalemic periodic paralysis
and the human skeletal muscle DHPR gene (CACNL1A3) on
chromosome lq [75].
Malignant hyperthermia and central core disease
Abnormalities in E-C coupling stemming from functional de-
fects in SR Ca2 release underlie other distinct phenotypes.
Malignant hyperthermia (MH) is a potentially lethal reaction to
frequently used inhaled anesthetics and muscle relaxants [76]. It is
characterized by an abrupt onset of accelerated muscle metabo-
lism, acidosis, rhabdomyolysis, muscle rigidity and marked eleva-
tion in body temperature. Malignant hyperthermia susceptibility
(MHS) is genetically transmitted as an autosomal dominant trait
in humans. A similar phenotype in pigs called the porcine stress
syndrome is well known in the pork industry as a cause of
devalued meat. Although swine are generally not subjected to
anesthetic agents, homozygous animals can develop an MH-like
reaction to acute stress prior to slaughter [77]. Porcine MH has
served as an experimental animal model in which to study the
basic cellular defects in this syndrome.
Since cytosolic Ca2 is important for skeletal muscle contrac-
tion and cellular metabolism, abnormalities in SR Ca2 release
were postulated to cause MHS. This hypothesis was supported by
the work of many investigators that demonstrated differences
between calcium release from normal and MHS SR membranes
[78, 79]. Furthermore, dantrolene, a drug which prevents SR Ca2
release, is effective treatment for MH [80]. Additional studies
more directly implicated structural and functional abnormalities
in the RyR protein making the gene encoding it a candidate for
this disease [81, 82].
The primary structure of the mammalian skeletal muscle RyR
was deduced by eDNA cloning and consists of> 5000 amino acids
with a predicted Mr > 550,000 [83]. Its predicted secondary
structure is consistent with two principle domains: a membrane
spanning channel-forming region near the carboxyl terminus and
a massive cytoplasmic domain compatible with the triad junction
foot Structures (Fig. 4). Heterologous expression of the cloned
cDNA in Chinese hamster ovary cells gives rise to ryanodine and
caffeine stimulated calcium release from intracellular stores and
high affinity [3H]ryanodine binding [84]. The human skeletal
muscle RyR cDNA exhibiting > 90% amino acid sequence
identity has also been cloned [85].
Genetic linkage studies greatly strengthened the hypothesis that
a relationship exists between the MHS phenotype and the RyR
gene (RYRI). The pig MH phenotype and the porcine iyrl gene
have been co-localized to chromosome 6p11-q21 suggesting link-
age [86]. In humans, polymorphisms within the RYRI gene or
nearby markers have been used to demonstrate tight linkage with
the MHS phenotype in many [87, 88], but not all pedigrees [89].
Further work identified missense mutations associated with MHS
first in the pig [90] and later in the human RYR1 gene [91]. In both
species, replacement of a similar arginine residue with cysteine
(pig codon 615, human codon 614) was found. This mutation
accounts for 5% of human MHS families studied to date, and
is the only known pig iyrl mutation. Two additional RYR1 gene
mutations have been reported in a limited number of MHS
pedigrees [92, 93]. Studies of reconstituted porcine RyR with the
R615C mutation reveal channels that exhibit greater open prob-
ability, longer mean open times, and reduced sensitivity to inhi-
bition by Ca2 relative to WT channels [94]. These kinetic
abnormalities may represent the primary biophysical defect in the
RyR responsible for MHS in the pig.
Another hereditary muscle disorder, central core disease
(CCD), also stems from mutations in the RYR1 gene. CCD is a
rare, autosomal dominant congenital myopathy characterized by
hypotonia and proximal muscle weakness presenting in infancy
[95]. The myopathy is generally non-progressive and there can be
variable expression within families. The name comes from the
characteristic histologic feature of myofibrillar "cores" seen with
histochemical staining of the muscle for oxidative enzymes. An
important associated clinical feature in CCD patients is MHS.
Many CCD patients have positive in vitro contracture tests and
can have episodes of MH. Because of the association with MHS,
genetic linkage studies were performed using markers in and
around the RYRJ gene. The results of these studies strongly
demonstrated linkage between the CCD phenotype and the RYRJ
locus. These observations suggested that CCD was likely to be
another manifestation of RYRJ mutations.
Two recent reports confirm this hypothesis with identification
of specific RYR1 mutations in CCD patients. Zhang et al exam-
ined the complete coding region of RYRI in a CCD proband by a
PCR based cDNA cloning approach [96]. Six nucleotide sequence
variants were discovered in this patient, but only one of these was
a likely mutation (histidine for arginine substitution at codon
2434). The R2434H mutation co-segregates with the CCD phe-
notype in a large Canadian family and is absent in the general
population. Two additional RYR1 mutations have also been found
in CCD patients by Quane et al [93]. Using SSCP to analyze
RT-PCR products from CCD muscle RNA, these investigators
identified two missense mutations (1403M, R163C) in four unre-
lated families with the disease. The R163C mutation was also
detected in two additional unrelated MHS patients who did not
have signs or symptoms of CCD. The role of RyR mutations in the
pathogenesis of CCD myopathy and whether they cause abnormal
E-C coupling are challenging questions.
Summary
In the last few years, identification of ion channel gene muta-
tions in various inherited diseases has contributed greatly to our
understanding of structure-function and the role of these impor-
tant molecules in normal physiology. As more and more informa-
tion emerges relating to ion transport protein structure and
biology, it is likely that other genetic disorders will be revealed as
ion channel diseases.
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